Veracyte Statistics
Total Valuation
Veracyte has a market cap or net worth of $2.42 billion. The enterprise value is $2.05 billion.
| Market Cap | 2.42B |
| Enterprise Value | 2.05B |
Important Dates
The next estimated earnings date is Wednesday, May 6, 2026, after market close.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Veracyte has 79.46 million shares outstanding. The number of shares has increased by 3.08% in one year.
| Current Share Class | 79.46M |
| Shares Outstanding | 79.46M |
| Shares Change (YoY) | +3.08% |
| Shares Change (QoQ) | +2.13% |
| Owned by Insiders (%) | 0.52% |
| Owned by Institutions (%) | 108.75% |
| Float | 79.02M |
Valuation Ratios
The trailing PE ratio is 37.12 and the forward PE ratio is 18.47.
| PE Ratio | 37.12 |
| Forward PE | 18.47 |
| PS Ratio | 4.68 |
| Forward PS | 4.12 |
| PB Ratio | 1.84 |
| P/TBV Ratio | 5.34 |
| P/FCF Ratio | 19.10 |
| P/OCF Ratio | 17.74 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.23, with an EV/FCF ratio of 16.15.
| EV / Earnings | 30.83 |
| EV / Sales | 3.96 |
| EV / EBITDA | 24.23 |
| EV / EBIT | 32.47 |
| EV / FCF | 16.15 |
Financial Position
The company has a current ratio of 8.15, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.15 |
| Quick Ratio | 7.63 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.38 |
| Debt / FCF | 0.31 |
| Interest Coverage | 62,987.00 |
Financial Efficiency
Return on equity (ROE) is 5.34% and return on invested capital (ROIC) is 6.56%.
| Return on Equity (ROE) | 5.34% |
| Return on Assets (ROA) | 2.91% |
| Return on Invested Capital (ROIC) | 6.56% |
| Return on Capital Employed (ROCE) | 4.68% |
| Weighted Average Cost of Capital (WACC) | 14.76% |
| Revenue Per Employee | $684,960 |
| Profits Per Employee | $87,885 |
| Employee Count | 755 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 6.81 |
Taxes
In the past 12 months, Veracyte has paid $1.85 million in taxes.
| Income Tax | 1.85M |
| Effective Tax Rate | 2.71% |
Stock Price Statistics
The stock price has increased by +1.06% in the last 52 weeks. The beta is 1.95, so Veracyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.95 |
| 52-Week Price Change | +1.06% |
| 50-Day Moving Average | 35.87 |
| 200-Day Moving Average | 34.81 |
| Relative Strength Index (RSI) | 35.65 |
| Average Volume (20 Days) | 1,062,316 |
Short Selling Information
The latest short interest is 5.38 million, so 6.77% of the outstanding shares have been sold short.
| Short Interest | 5.38M |
| Short Previous Month | 5.49M |
| Short % of Shares Out | 6.77% |
| Short % of Float | 6.81% |
| Short Ratio (days to cover) | 5.82 |
Income Statement
In the last 12 months, Veracyte had revenue of $517.15 million and earned $66.35 million in profits. Earnings per share was $0.82.
| Revenue | 517.15M |
| Gross Profit | 373.20M |
| Operating Income | 62.99M |
| Pretax Income | 68.20M |
| Net Income | 66.35M |
| EBITDA | 84.40M |
| EBIT | 62.99M |
| Earnings Per Share (EPS) | $0.82 |
Balance Sheet
The company has $412.89 million in cash and $39.65 million in debt, with a net cash position of $373.24 million or $4.70 per share.
| Cash & Cash Equivalents | 412.89M |
| Total Debt | 39.65M |
| Net Cash | 373.24M |
| Net Cash Per Share | $4.70 |
| Equity (Book Value) | 1.31B |
| Book Value Per Share | 16.50 |
| Working Capital | 428.44M |
Cash Flow
In the last 12 months, operating cash flow was $136.31 million and capital expenditures -$9.68 million, giving a free cash flow of $126.63 million.
| Operating Cash Flow | 136.31M |
| Capital Expenditures | -9.68M |
| Depreciation & Amortization | 21.42M |
| Net Borrowing | n/a |
| Free Cash Flow | 126.63M |
| FCF Per Share | $1.59 |
Margins
Gross margin is 72.17%, with operating and profit margins of 12.18% and 12.83%.
| Gross Margin | 72.17% |
| Operating Margin | 12.18% |
| Pretax Margin | 13.19% |
| Profit Margin | 12.83% |
| EBITDA Margin | 16.32% |
| EBIT Margin | 12.18% |
| FCF Margin | 24.49% |
Dividends & Yields
Veracyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.08% |
| Shareholder Yield | -3.08% |
| Earnings Yield | 2.74% |
| FCF Yield | 5.24% |
Analyst Forecast
The average price target for Veracyte is $44.33, which is 45.63% higher than the current price. The consensus rating is "Buy".
| Price Target | $44.33 |
| Price Target Difference | 45.63% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 10.88% |
| EPS Growth Forecast (5Y) | 21.52% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Veracyte has an Altman Z-Score of 17.07 and a Piotroski F-Score of 7.
| Altman Z-Score | 17.07 |
| Piotroski F-Score | 7 |